预约演示
更新于：2025-08-21
Teicoplanin
替考拉宁
更新于：2025-08-21
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)临床前 |
特殊审评孤儿药 (美国)、孤儿药 (欧盟) |
登录后查看时间轴
关联
37
项与 替考拉宁 相关的临床试验NCT06818565
Comparison of Efficacy and Safety of Ceftazidime Avibactam Versus Extended Infusions of High Dose Meropenem in Patients of ACLF With Nosocomial Infections.
NCT06426212
Use of Teicoplanin on a Three-weekly Administration in the Complex Outpatient Macroactivity Regimen of Infectious Diseases Unit in the Alessandro Manzoni Hospital (Lecco, Italy)
EUCTR2023-000005-12-IT
An open-label study to evaluate the safety and tolerability of inhaled Teicoplanin in the treatment of Staphylococcus aureus (including mrsa) infections in CYSTIC FIBROSIS PATIENTS - study to evaluate the safety of inhaled Teicoplanin in the treatment of Stafilococco infections
100 项与 替考拉宁 相关的临床结果
登录后查看更多信息
100 项与 替考拉宁 相关的转化医学
登录后查看更多信息
100 项与 替考拉宁 相关的专利（医药）
登录后查看更多信息
4,301
项与 替考拉宁 相关的文献（医药）2025-12-31Emerging Microbes & Infections
Genomic islands and molecular mechanisms relating to drug-resistance in
Clostridioides
(
Clostridium
)
difficile
PCR ribotype 176
Article
作者: Soltesova, Anna ; Pituch, Hanna ; Kuijper, Ed ; Balikova Novotna, Gabriela ; Brajerova, Marie ; Prasad, Suhanya ; Zikova, Jaroslava ; Demay, Fanny ; Novakova, Elena ; Kovarovic, Vojtech ; Krutova, Marcela ; Smits, Wiep Klaas
OBJECTIVES:
To analyse characteristics of Clostridioides difficile PCR ribotype 176 clinical isolates from Poland, the Czech Republic and Slovakia with regard to the differences in its epidemiology.
METHODS:
Antimicrobial susceptibility testing and whole genome sequencing were performed on a selected group of 22 clonally related isolates as determined by multilocus variable-number tandem repeat analysis (n = 509). Heterologous expression and functional analysis of the newly identified methyltransferase were performed.
RESULTS:
Core genome multilocus sequence typing found 10-37 allele differences. All isolates were resistant to fluoroquinolones (gyrA_p. T82I), aminoglycosides with aac(6')-Ie-aph(2'')-Ia in six isolates. Erythromycin resistance was detected in 21/22 isolates and 15 were also resistant to clindamycin with ermB gene. Fourteen isolates were resistant to rifampicin with rpoB_p. R505K or p. R505K/H502N, and five to imipenem with pbp1_p. P491L and pbp3_p. N537K. PnimBG together with nimB_p. L155I were detected in all isolates but only five were resistant to metronidazole on chocolate agar. The cfrE, vanZ1 and cat-like genes were not associated with linezolid, teicoplanin and chloramphenicol resistance, respectively. The genome comparison identified six transposons carrying antimicrobial resistance genes. The ermB gene was carried by new Tn7808, Tn6189 and Tn6218-like. The aac(6')-Ie-aph(2'')-Ia were carried by Tn6218-like and new Tn7806 together with cfrE gene. New Tn7807 carried a cat-like gene. Tn6110 and new Tn7806 contained an RlmN-type 23S rRNA methyltransferase, designated MrmA, associated with high-level macrolide resistance in isolates without ermB gene.
CONCLUSIONS:
Multidrug-resistant C. difficile PCR ribotype 176 isolates carry already described and unique transposons. A novel mechanism for erythromycin resistance in C. difficile was identified.
2025-12-01DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
The aetiologic agents and resistance rates in community-acquired complicated intra-abdominal infections: Where are we locally?
Article
作者: Gulten, Ezgi ; Ontas, Eray ; Ersoz, Siyar ; Saricaoglu, Elif Mukime ; Akdemir, Irem ; Memikoglu, Kemal Osman ; Cinar, Gule ; Ozturk, Eren
BACKGROUND:
Community-acquired complicated intra-abdominal infections (CA-cIAIs) are a significant global health concern, associated with considerable morbidity and mortality. In regions lacking local epidemiological data, obtaining intraoperative cultures is recommended to guide empirical antibiotic selection. This study aimed to describe the local microbiological profile and resistance patterns in CA-cIAIs.
METHODS:
We retrospectively reviewed adult patients operated for CA-cIAIs at Ankara University Hospital between January 2018 and December 2023. Inclusion criteria included intraoperative or percutaneous drainage sampling and absence of recent hospitalization or abdominal procedures within three months.
RESULTS:
Among 124 surgical patients, cultures were collected from 80 (64.5 %), with 44 (70 %) yielding microbiological growth. A total of 69 pathogens were identified. The most frequent infection sources were cholecystitis (36 %), appendicitis (27 %), and colon perforation (20 %). Escherichia coli (46.4 %), Klebsiella pneumoniae (10.1 %), and Enterococcus faecalis (8.7 %) were the predominant organisms. Extended-spectrum beta-lactamase (ESBL) production was observed in 30.4 % of Gram-negative strains, with notable resistance to third-generation cephalosporins (40 %) and fluoroquinolones (33.3 %). Empirical antibiotics included piperacillin-tazobactam (77.2 %) and teicoplanin (47.7 %). However, their predictive values were low (PPV: 32.4 % and 38.1 %, respectively), with moderate concordance rates.
CONCLUSIONS:
E. coli remains the leading pathogen in CA-cIAIs, but rising resistance rates to key antibiotics pose challenges to empirical treatment. Although piperacillin-tazobactam and teicoplanin were the most commonly used empirical agents, their low PPV underscore the need for improved strategies to optimize empirical therapy. Our findings emphasize the importance of obtaining intraoperative cultures to enable timely de-escalation and appropriate antimicrobial stewardship.
2025-09-01BRAZILIAN JOURNAL OF MICROBIOLOGY
Antimicrobial resistance and virulence potential of non-faecium and non-faecalis enterococci isolated from canine rectal swabs
Article
作者: Neves, Felipe Piedade Gonçalves ; Martins, Ianick Souto ; Marassi, Carla Dray ; Rabello, Renata Fernandes ; Coutinho, Lidiane Lamara Silva ; Sabino, Hellen Dos Santos ; Dieckmann, Ana Maria
Animals can serve as reservoirs for multidrug-resistant (MDR) enterococci with potential pathogenicity. Close contact between dogs and their owners may facilitate the interspecies transmission of these bacterial agents, potentially impacting human health. While Enterococcus faecium and Enterococcus faecalis are the main species implicated in healthcare-associated infections (HAIs), non-faecium and non-faecalis (NFF) enterococci, though less prevalent, may also contribute to infections. This study aimed to assess the antimicrobial resistance phenotypes and genotypes and virulence potential of NFF enterococci isolated from asymptomatic dogs. A total of 114 NFF enterococcal isolates were obtained from rectal swabs of dogs, between 2015 and 2017, in Rio de Janeiro, Brazil. Antimicrobial resistance was assessed using disk diffusion and agar gradient diffusion methods, and resistance and virulence genes were determined by polymerase chain reaction (PCR). The highest resistance frequencies were observed for rifampicin (38.6%), tetracycline (27.2%), and erythromycin (15.8%). One vancomycin-resistant E. gallinarum strain (MIC > 512 µg/mL) was isolated, and it also exhibited resistance to teicoplanin. High-level resistance to streptomycin (HLR-S) was found in E. canintestini (22.2%), E. gallinarum (8.5%), and E. avium (7.1%) strains. Most E. raffinosus strains were resistant to ampicillin (55%) and penicillin G (55%), and this was the only species resistant to ampicillin. MDR strains accounted for 14.9% of the strains, with MDR colonization more frequent in purebred dogs, suggesting a possible breed-related association. The resistance genes detected included ant(6)-Ia, tet(M), tet(L), erm(B), and the van operon. Virulence genes were detected in a limited number of strains: esp (11.4%), gelE (2.6%), asa1 (0.9%), and hyl (0.9%). The presence of esp was significantly associated with E. canintestini (44.4%), and E. avium (42.9%). Further studies are needed to evaluate the public health implications of these findings.
100 项与 替考拉宁 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 囊性纤维化 | 临床1期 | 意大利 | 2019-10-25 | |
| 囊性纤维化 | 临床1期 | 意大利 | 2019-10-25 | |
| 埃博拉病毒性疾病 | 临床前 | 中国 | 2016-04-01 | |
| 严重急性呼吸综合征 | 临床前 | 中国 | 2016-04-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 44 | Teicoplanin lock therapy | 糧遞醖繭壓選顧鹹壓艱(鏇醖築鏇選範鹽顧糧構) = 鬱繭壓遞艱觸積願網襯 鬱構願壓鏇鏇醖鑰糧艱 (構製簾憲廠構願餘廠顧 ) 更多 | 积极 | 2009-11-01 | ||
Vancomycin lock therapy | 糧遞醖繭壓選顧鹹壓艱(鏇醖築鏇選範鹽顧糧構) = 遞鹹淵膚鹽糧觸鏇糧壓 鬱構願壓鏇鏇醖鑰糧艱 (構製簾憲廠構願餘廠顧 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用